Artificial intelligence and computational tools continue to reshape biotechnology. Qiagen launched a digital PCR partnership program to accelerate clinical assay development through external collaborations, aiming to expand its QiAcuityDx platform’s diagnostic menu and patient impact. The Arc Institute initiated the Virtual Cell Challenge, a premier AI competition supported by Nvidia and genomic companies to develop predictive models of gene perturbation effects from complex single-cell transcriptomics data, promising to propel drug discovery. Meanwhile, biotech CEOs, including Merck’s Robert Davis, underscore AI and machine learning as strategic priorities in drug development, signaling a substantial increase in AI-driven innovations across R&D pipelines.